MORC3
MORC family CW-type zinc finger protein 3
Also known as: KIAA0136, MORC3_HUMAN, NXP2, ZCW5, ZCWCC3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14149
- Gene
- MORC3
- Ensembl
- ENSG00000159256
- Chromosome
- 21
- Canonical length
- 939 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Mitochondria
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a protein that localizes to the nuclear matrix and forms nuclear bodies via an ATP-dependent mechanism. The protein is predicted to have coiled-coil and zinc finger domains and has RNA binding activity. Alternative splicing produces multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Feb 2016]
Canonical amino-acid sequenceUniProt
939 residues, UniProt reviewed canonical sequence.
>Q14149|MORC3
1 MAAQPPRGIR LSALCPKFLH TNSTSHTWPF SAVAELIDNA YDPDVNAKQI WIDKTVINDH
61 ICLTFTDNGN GMTSDKLHKM LSFGFSDKVT MNGHVPVGLY GNGFKSGSMR LGKDAIVFTK
121 NGESMSVGLL SQTYLEVIKA EHVVVPIVAF NKHRQMINLA ESKASLAAIL EHSLFSTEQK
181 LLAELDAIIG KKGTRIIIWN LRSYKNATEF DFEKDKYDIR IPEDLDEITG KKGYKKQERM
241 DQIAPESDYS LRAYCSILYL KPRMQIILRG QKVKTQLVSK SLAYIERDVY RPKFLSKTVR
301 ITFGFNCRNK DHYGIMMYHR NRLIKAYEKV GCQLRANNMG VGVVGIIECN FLKPTHNKQD
361 FDYTNEYRLT ITALGEKLND YWNEMKVKKN TEYPLNLPVE DIQKRPDQTW VQCDACLKWR
421 KLPDGMDQLP EKWYCSNNPD PQFRNCEVPE EPEDEDLVHP TYEKTYKKTN KEKFRIRQPE
481 MIPRINAELL FRPTALSTPS FSSPKESVPR RHLSEGTNSY ATRLLNNHQV PPQSEPESNS
541 LKRRLSTRSS ILNAKNRRLS SQFENSVYKG DDDDEDVIIL EENSTPKPAV DHDIDMKSEQ
601 SHVEQGGVQV EFVGDSEPCG QTGSTSTSSS RCDQGNTAAT QTEVPSLVVK KEETVEDEID
661 VRNDAVILPS CVEAEAKIHE TQETTDKSAD DAGCQLQELR NQLLLVTEEK ENYKRQCHMF
721 TDQIKVLQQR ILEMNDKYVK KETCHQSTET DAVFLLESIN GKSESPDHMV SQYQQALEEI
781 ERLKKQCSAL QHVKAECSQC SNNESKSEMD EMAVQLDDVF RQLDKCSIER DQYKSEVELL
841 EMEKSQIRSQ CEELKTEVEQ LKSTNQQTAT DVSTSSNIEE SVNHMDGESL KLRSLRVNVG
901 QLLAMIVPDL DLQQVNYDVD VVDEILGQVV EQMSEISSTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MORC3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 33 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 33 nTPM
- lymph node: 19 nTPM
- ovary: 19 nTPM
- tonsil: 19 nTPM
- thymus: 18 nTPM
- spleen: 18 nTPM
Single-cell type
- urothelial cells: 215 nCPM
- neutrophils: 205 nCPM
- ocular epithelial cells: 185 nCPM
- esophageal apical cells: 172 nCPM
- erythrocyte progenitors: 156 nCPM
- suprabasal keratinocytes: 154 nCPM
Immune cell
- basophil: 33 nTPM
- eosinophil: 20 nTPM
- non-classical monocyte: 14 nTPM
- neutrophil: 14 nTPM
- T-reg: 13 nTPM
- naive B-cell: 13 nTPM
Brain region
- cerebellum: 33 nTPM
- white matter: 29 nTPM
- spinal cord: 23 nTPM
- cerebral cortex: 22 nTPM
- medulla oblongata: 22 nTPM
- pons: 21 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MORC3.
Disease | AutoantibodyPubMed
Conditions in which antibodies against MORC3 are reported. Each links to that disease's full target list.
- Dermatomyositis 61
- Myositis 29
- Lung Diseases, Interstitial 15
- Calcinosis 12
- Muscle Weakness 8
- Polymyositis 7
Showing 6 of 7 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for MORC3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
102 publications
- Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
2013 · Arthritis Rheum · RCR 10.6 · 298 citations - Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.
2017 · Arthritis Care Res (Hoboken) · RCR 7.4 · 138 citations - Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
2012 · Ann Rheum Dis · RCR 6.9 · 190 citations - The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis.
2020 · J Clin Med · RCR 6.5 · 76 citations - Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
2022 · Rheumatology (Oxford) · RCR 6.5 · 51 citations
Show 20 more of 102 total
- Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
2017 · Arthritis Res Ther · RCR 6.3 · 134 citations - Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
2016 · J Immunol Methods · RCR 5.5 · 119 citations - Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.
2009 · Arthritis Rheum · RCR 5.3 · 169 citations - Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.
2017 · Arthritis Care Res (Hoboken) · RCR 5.2 · 91 citations - Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
2014 · Rheumatology (Oxford) · RCR 5.1 · 122 citations - Recent advances in dermatomyositis-specific autoantibodies.
2016 · Curr Opin Rheumatol · RCR 5 · 112 citations - Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
2022 · Clin Rev Allergy Immunol · RCR 4.9 · 51 citations - New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review.
2022 · Rheumatol Int · RCR 4 · 42 citations - Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
2014 · JAMA Dermatol · RCR 3.9 · 84 citations - Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
2020 · JAMA Neurol · RCR 3.4 · 51 citations - Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
2021 · Rheumatology (Oxford) · RCR 2.7 · 31 citations - Myositis Specific Autoantibodies: A Clinical Perspective.
2020 · Open Access Rheumatol · RCR 2.6 · 31 citations - Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients.
2019 · J Transl Autoimmun · RCR 2.4 · 42 citations - Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
2023 · Clin Rheumatol · RCR 2.4 · 9 citations - Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
2018 · Rheumatology (Oxford) · RCR 2.4 · 48 citations - Clinical significance of myositis-specific autoantibodies.
2018 · Immunol Med · RCR 2.4 · 43 citations - Circulating cell-free DNA promotes inflammation in dermatomyositis patients with anti-NXP2 antibodies via the cGAS/STING pathway.
2025 · Rheumatology (Oxford) · RCR 2.3 · 7 citations - An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.
2022 · Clin Rev Allergy Immunol · RCR 2.1 · 18 citations - Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.
2017 · Clin Exp Rheumatol · RCR 2 · 34 citations - Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology.
2021 · Arthritis Rheumatol · RCR 2 · 28 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.22
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.89
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antiviral innate immune response
- maintenance of protein location in nucleus
- negative regulation of fibroblast proliferation
- negative regulation of interferon-beta production
- negative regulation of transcription by RNA polymerase II
- peptidyl-serine phosphorylation
- positive regulation of cellular senescence
- post-embryonic development
- protein phosphorylation
- protein stabilization
Molecular functions
- ATP hydrolysis activity
- DNA binding
- histone H3K4me3 reader activity
- protein-macromolecule adaptor activity
- RNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MORC3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MORC3 as an antibody target. Whether an autoantibody or antibody against MORC3 could matter depends on whether native MORC3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MORC3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MORC3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...